Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan to pembrolizumab improves disease-free survival, building on prior advances and signaling a potential new standard pending overall survival data. In later-line disease, lenvatinib plus belzutifan delivers strong response rates and progression-free survival with manageable toxicity. Overall, these findings suggest belzutifan will be used earlier in the treatment pathway, offering greater disease control and expanding therapeutic options in RCC.
KEYNOTE-B61 and LITESPARK-011: Evolving RCC Treatment Strategies
Dr. Elizabeth Plimack reviews how KEYNOTE-B61 supports lenvatinib plus pembrolizumab as a strong frontline option in non–clear cell RCC, particularly
